A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
Status:
Withdrawn
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This phase 2 trial will evaluate the activity of Panobinostat in combination with Everolimus
for children with gliomas harboring H3.1 or H3.3K27M mutation, including newly diagnosed
high-grade glioma or DIPG (diffuse intrinsic pontine glioma) after radiation (stratum A) and
recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center